3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
29
Stomach Neoplasms
13
Esophageal Neoplasms
13
Colorectal Neoplasms
12
Esophageal Squamous Cell Carcinoma
10
Rectal Neoplasms
7
Pancreatic Neoplasms
7
Biliary Tract Neoplasms
7
Head and Neck Neoplasms
5
Colonic Neoplasms
5
Cholangiocarcinoma
5
Carcinoma, Non-Small-Cell Lung
5
Neoplasm Metastasis
4
Locally Advanced Rectal Cancer
4
Liver Neoplasms
4
Ovarian Neoplasms
3
Neoplasms
3
Melanoma
3
Carcinoma, Renal Cell
3
Anus Neoplasms
3
Turcot syndrome
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Pathologic Complete Response
2
Gastric / Gastroesophageal Junction Adenocarcinoma
2
Digestive System Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Spinocerebellar Degenerations
1
Interventions
pembrolizumab
29
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Trastuzumab
8
Nivolumab
8
Cisplatin
8
Taxes
7
Gemcitabine
7
Bevacizumab
6
Specimen Handling
5
Oxaliplatin
5
Irinotecan
5
Fluorouracil
5
Cetuximab
5
Biopsy
5
spartalizumab
4
Leucovorin
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
durvalumab
3
atezolizumab
3
aldesleukin
3
X-Rays
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Interviews as Topic
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Immune Checkpoint Inhibitors
×
Gastrointestinal
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled